Shatterproof Statement on the Passage of the Big Beautiful Bill
At the same time, we are deeply concerned about the bill's potential impact on access to treatment for individuals living with substance use disorder (SUD). Medicaid is the nation's single largest payer of addiction treatment services—serving a population in which 21% are impacted by SUD, compared to 16% of those with commercial insurance.
The impact on Medicaid is likely to have a harmful ripple effect across the healthcare system. At a time when overdoses remain at crisis levels, states need greater – not fewer – resources to meet the critical needs of families and communities to prevent and treat SUD. In 2024, nearly 250,000 deaths were attributed to overdoses and/or alcohol use disorder, in addition to untold societal and economic costs.
Shatterproof remains committed to ensuring individuals and families affected by addiction have access to evidence-based, lifesaving care. We urge Congress to prioritize support for essential infrastructure during the FY2026 appropriations process, including support for the National Survey on Drug Use and Health and funding to improve findtreatment.gov, the national treatment locator, by incorporating meaningful quality metrics.
Shatterproof stands as a nonpartisan, evidence-driven resource committed to supporting those affected by addiction and creating a more resilient nation.
About Shatterproof
Shatterproof is a national nonprofit organization dedicated to reducing the burden of substance use disorder in the United States. Shatterproof is focused on increasing access to quality, science-based addiction treatment; educating society on prevention, treatment and recovery; driving change through public policy; and reducing addiction stigma to ensure that people who use substances or have a substance use disorder can live healthy and fulfilled lives. Shatterproof operates with three imperatives: base everything on science; help people today while also catalyzing partnerships to improve the healthcare system for future generations; and follow rigorous metrics for maximum impact. Find Shatterproof on Facebook, X and YouTube: @ShatterproofHQ or follow us on Instagram at @weareshatterproof. To learn more, visit www.Shatterproof.org.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
5 hours ago
- Malaysian Reserve
Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025
SHANGHAI and HONG KONG, July 28, 2025 /PRNewswire/ — Antengene Corporation Limited ('Antengene', SEHK: a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for cancer, today announced that an abstract featuring the latest data from a Phase I/II study of the Claudin 18.2 antibody-drug conjugate (ADC), ATG-022, has been accepted for poster presentation at the 2025 European Society for Medical Oncology Annual Congress (ESMO 2025), taking place from October 17th to October 21st at the Messe Berlin in Berlin, Germany. Details of the Poster Presentation: ATG-022 (Claudin 18.2 antibody-drug conjugate)Title: Phase I/II study of Claudin 18.2 ADC ATG-022 in patients with advanced gastric/ gastroesophageal junction cancer (CLINCH)Abstract Number: 2907Presentation Number: 2113PDate: October 19, 2025 About ATG-022 ATG-022 is an antibody-drug conjugate (ADC) designed to target CLDN18.2, a member of the Claudin family of cell adhesion molecules. Under normal conditions, Claudins are located within tight junctions between cells, forming a barrier to regulate cell permeability. However, in cancer, Claudins are aberrantly expressed on the cell surface due to changes in cell polarity. CLDN18.2 is frequently overexpressed in a range of primary malignant tumors, including gastric, esophageal, cholangiocarcinoma, and pancreatic cancers. The U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designations to ATG-022, for gastric and pancreatic cancers. Data from the ongoing CLINCH study demonstrated that ATG-022 delivers robust efficacy across all levels of CLDN18.2 expression in gastric cancer patients, including those with high, low, and ultra-low expression. This broad activity positions ATG-022 as a potential market leader, capable of addressing the largest patient population with CLDN18.2-positive tumors. Furthermore, the strong efficacy observed in patients with low CLDN18.2 expression suggests promise for treating other tumor types with similar expression profiles. About Antengene Antengene Corporation Limited ('Antengene', SEHK: is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of 'Treating Patients Beyond Borders'. Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact: Investor Contacts: Donald LungE-mail: Mobile: +86 18420672158 PR Contacts:Peter QianE-mail: Mobile: +86 13062747000
New Straits Times
a day ago
- New Straits Times
#SHOWBIZ: Elyana's post on chemotherapy session: 'Only those who experience it will know'
KUALA LUMPUR: An Instagram (IG) post uploaded by singer Elyana last night has captured the attention of netizens, who are generally speculating about the singer's latest health status. This follows her previous confirmation of being cancer-free, with her recent photos and captions sparking renewed concern. In her post, the 38-year-old artiste, whose real name is Erneelya Elyana Emrizal, shared a caption that appears to describe her emotional turmoil. Elyana also included a photo, believed to be a recent image, showing her head smooth and hairless. Netizens believe this could be a result of chemotherapy as a preventive treatment. Elyana, well-known for her song "Niat," shared the following caption: "The process of our lives, only we go through, only we know. Trying desperately to appear calm and sane without telling anyone." "My message to my fellow fighters.... You are valuable and you are worthy enough to always be celebrated." "No matter how much or how little you have, remain a good person even if they insult you badly." The post has since received nearly 22,000 likes and over 750 comments. Fans and celebrity friends alike have largely posted positive comments, offering prayers for Elyana's well-being and wishing her the best of health. In previous reports late last year, Elyana surprised her fans by revealing that she was still undergoing chemotherapy as follow-up treatment. "Praise be to God, the doctor confirmed that I was cancer-free two years ago. However, chemotherapy treatment sessions are needed to prevent the disease from recurring," she said. "I need to undergo 12 rounds of chemotherapy treatment, and this procedure is performed at a medical centre in Subang Jaya, Selangor." "For now, the doctor recommends that I complete four cycles first. Then, the doctor will conduct further examinations to determine whether or not chemotherapy treatment should be continued," she said at the time. Elyana was reportedly hesitant to be certain whether she had truly recovered, as her follow-up treatment was a preventive measure.
Malaysian Reserve
2 days ago
- Malaysian Reserve
IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation
Breast surgeon, Professor Eisuke Fukuma, a highly regarded cryoablation expert & ProSense® user at Kameda Medical Center, presented updated breast cancer cryoablation data from an independent study of over 600 women from 2006 to 2023 Independent ProSense® study by Professor Hisanori Kawamoto demonstrating 0% breast cancer local recurrence wins Best of Breast Cancer Award Leading US Breast Surgeon, Dr. Richard Fine, presented data from IceCure's ICE3 study & discussed other recent publications on breast cancer cryoablation CAESAREA, Israel, July 25, 2025 /PRNewswire/ — IceCure Medical Ltd. (Nasdaq: ICCM) ('IceCure', 'IceCure Medical' or the 'Company'), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its participation in the 33rd Annual Meeting of the Japanese Breast Cancer Society's Conference (the 'Conference') which took place earlier this month in Tokyo. 'We believe ProSense® can make a significant impact on improving breast cancer outcomes in Japan by providing women with a minimally invasive option. This year's Conference was highly productive as we engaged with breast surgeons, thought leaders, and industry participants,' stated Eyal Shamir, IceCure's Chief Executive Officer. 'Working with Terumo Corporation in Japan, the country's largest medical device company, we anticipate strong commercial adoption upon regulatory approval for breast cancer, especially given the strong data coming from independent Japanese studies.' IceCure, a sponsor of the Conference, hosted a cryoablation-focused luncheon on Friday, July 11, 2025, led by Professor Takayuki Kinoshita, Division of Breast Surgery, NHO Tokyo Medical Center, with presentations made by: Professor Eisuke Fukuma, who has performed over 600 breast cryoablation procedures, the majority of which were conducted with ProSense®, presented the latest data from his ongoing activity to treat breast cancer at Kameda Medical Center. Professor Fukuma's presentation included the following: From June 2006 through December 2023, 535 breast cancer patients with tumor lesions of less than 15 millimeters and 76 patients with tumor lesions of less than 10 millimeters were treated. The overall ipsilateral breast tumor recurrence rate (IBTR') was 0.98% for up to 17 years, resulting in a 99.02% recurrence free rate. For a subpopulation with more than 10 years follow up, including 51 patients with invasive ductal carcinoma and 20 patients with ductal carcinoma in situ, the IBTR was 2.8%, resulting in a 97.2% recurrence free rate. From June 2006 through December 2023, 535 breast cancer patients with tumor lesions of less than 15 millimeters and 76 patients with tumor lesions of less than 10 millimeters were treated. The overall ipsilateral breast tumor recurrence rate (IBTR') was 0.98% for up to 17 years, resulting in a 99.02% recurrence free rate. For a subpopulation with more than 10 years follow up, including 51 patients with invasive ductal carcinoma and 20 patients with ductal carcinoma in situ, the IBTR was 2.8%, resulting in a 97.2% recurrence free rate. Dr. Richard Fine of West Cancer Center & Research Institute in the U.S., and a clinical investigator of IceCure's successfully completed ICE3 breast cancer clinical study, presented findings from the ICE3 study as well as data from independent studies of ProSense® in breast cancer. The Conference gave the Best of Breast Cancer award to an independent study published in the journal Breast Cancer titled 'Percutaneous ultrasound–guided cryoablation for early–stage primary breast cancer: a follow–up study in Japan'. This study was led by Professor Hisanori Kawamoto, M.D., Ph.D. from the Department of Breast Surgery, Breast and Imaging Center at St. Marianna University School of Medicine in Japan and reported zero (0%) breast cancer local recurrence 5 years following treatment with ProSense®. Dr. Kawamoto commented, 'This is a very important study in Japan, where we are experiencing an upward trend in breast cancer cases, especially among women in their late 40s to their early 60s. These are women who often are at very active stages of their life and therefore there is a growing demand for treatment options that minimize the chance of, or even avoid, hospitalization, in addition to resulting in favorable clinical and cosmetic outcomes. We are very pleased with these results and are hopeful that ProSense® may become a favored option in Japan upon regulatory approval for early-stage breast cancer.' Terumo Corporation is expected to submit an application to the Pharmaceuticals and Medical Devices Agency ('PMDA') of Japan for regulatory clearance for breast cancer indication for the ProSense® system by the end of 2025. About ProSense®The ProSense® Cryoablation System provides a minimally invasive treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver. ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedures for breast tumors. About IceCure MedicalIceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia. Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the belief that ProSense® can make a significant impact on improving breast cancer outcomes in Japan; the Company's anticipation of strong commercial adoption upon regulatory approval of ProSense® for breast cancer; the belief of the importance of 'Percutaneous ultrasound–guided cryoablation for early–stage primary breast cancer: a follow–up study in Japan;' and that Terumo Corporation is expected to submit a PMDA application for regulatory clearance for breast cancer indication for the ProSense® system by the end of 2025. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. References and links to websites have been provided in this press release as a convenience, and the information contained on such websites is not incorporated by reference herein. IR Contact: Email: investors@ Michael Polyviou Phone: 732-232-6914 Logo – View original content:
